Liu, Joyce F <br/><br/>
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.  [electronic resource] 

 -  JAMA oncology  12 2019 
 - 1731-1738 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2019.3343  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intravenous<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Carcinoma, Ovarian Epithelial--drug therapy<br/>Drug Administration Schedule<br/>Drug Synergism<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Nivolumab--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome<br/>United States